|
시장보고서
상품코드
1546126
뎅기열 백신 시장 규모 : 백신 유형, 백신 단계, 유통 채널, 지역별 전망, 경쟁 전략, 부문 예측(-2033년)Dengue Vaccines Market Size- By Type of Vaccine, By Vaccine Phase, By Distribution Channel- Regional outlook, Competitive Strategies and Segment Forecast to 2033 |
||||||
세계 뎅기열 백신 시장 규모는 예측 기간 동안 13.11%의 연평균 복합 성장률(CAGR)을 나타내고, 2033년에는 18억 1,395만 달러 규모로 성장할 것으로 예상됩니다.
세계 뎅기열 백신(Dengue Vaccine) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각종 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 시장 역학
- 성장 촉진요인 및 억제요인, 기회, 과제 분석
- 시장에 대한 COVID-19의 영향
제5장 시장 변수와 전망
- SWOT 분석
- PESTEL 분석
- Porter의 Five Forces 분석
- 히트맵 분석
제6장 경쟁 구도
- 제조거점 분포·판매 지역·제품 유형
- 인수합병(M&A)·제휴·제품 발매·협력
제7장 세계의 뎅기열 백신 시장 : 백신 유형별
- 세계 시장 규모·점유율·예측
- 생약독화 백신
- 재조합 백신
제8장 세계의 뎅기열 백신 시장 : 백신 단계별
- 세계 시장 규모·점유율·예측
- 단계 I
- 단계 II
- 단계 III
제9장 세계의 뎅기열 백신 시장 : 유통 채널별
- 세계 시장 규모·점유율·예측
- 합성
- 바이오
제10장 세계의 뎅기열 백신 시장 예측
- 시장 규모·시장 점유율
제11장 세계의 뎅기열 백신 시장 : 지역별
- 시장 규모·시장 점유율 추이·예측
- 아시아태평양
- 유럽
- 중동 및 아프리카
- 북미
- 라틴아메리카
제12장 기업 개요
- Butantan Institute
- GeneOne Life Science Inc.
- GlaxoSmithKline Plc
- Mylan N.V.
- Medigen Vaccine Biologics Corporation
- Merck and Co. Inc.
- Nunn's Home Medical Equipment Company Ltd.
- Panacea Biotec Limited
- Sanofi Pasteur Limited
- Serum Institute of India Pvt. Ltd.
제13장 결론
제14장 약어 리스트
제15장 참고 링크
LSH 24.09.12Dengue Vaccines Market Introduction and Overview
According to SPER Market Research, 'Dengue Vaccines Market Size- By Type of Vaccine, By Vaccine Phase, By Distribution Channel - Regional outlook, Competitive Strategies and Segment Forecast to 2033' States that the Global Dengue Vaccines Market is estimated to reach USD 1813.95 million by 2033 with a CAGR of 13.11 %.
Dengue vaccines are designed to prevent dengue fever, a tropical illness spread by Aedes mosquitoes. The primary challenge in developing these vaccines lies in addressing the four different dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
The focus on COVID-19 diverted resources, funding, and research efforts away from other infectious diseases, including dengue. This shift has slowed progress in the development and approval of new dengue vaccines.
Scope of the report:
Report Metric Details
Market size available for years 2020-2033
Base year considered 2023
Forecast period 2024-2033
Segments covered By Type of Vaccine, By Vaccine Phase, By Distribution Channel
Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
Companies Covered Butantan Institute, GeneOne Life Science Inc., GlaxoSmithKline Plc, Mylan N.V., Medigen Vaccine Biologics Corporation, Merck and Co. Inc., Nunn's Home Medical Equipment Company Ltd., Panacea Biotec Limited, Sanofi Pasteur Limited, Serum Institute of India Pvt Ltd.
Global Dengue Vaccines Market Segmentation:
By Type of Vaccine: Based on the Type of Vaccine, Global Dengue Vaccines Market is segmented as; Live Attenuated Vaccines, Recombinant Vaccines.
By Vaccine Phase: Based on the Vaccine Phase, Global Dengue Vaccines Market is segmented as; Phase I, Phase II, Phase III.
By Distribution Channel: Based on the Distribution Channel, Global Dengue Vaccines Market is segmented as; Hospitals, Clinics, Retail Pharmacies.
By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 4.2. COVID-19 Impacts of the Global Dengue Vaccines Market
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Dengue Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type of Vaccine
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Dengue Vaccines Market
7. Global Dengue Vaccines Market, By Type of Vaccine (USD Million) 2020-2033
- 7.1. Global Dengue Vaccines Market Size, Share and Forecast, By Type of Vaccine, 2020-2026
- 7.2. Global Dengue Vaccines Market Size, Share and Forecast, By Type of Vaccine, 2027-2033
- 7.3. Live Attenuated Vaccines
- 7.4. Recombinant Vaccines
8. Global Dengue Vaccines Market, By Vaccine Phase (USD Million) 2020-2033
- 8.1. Global Dengue Vaccines Market Size, Share and Forecast, By Vaccine Phase, 2020-2026
- 8.2. Global Dengue Vaccines Market Size, Share and Forecast, By Vaccine Phase, 2027-2033
- 8.3. Phase I
- 8.4. Phase II
- 8.5. Phase III
9. Global Dengue Vaccines Market, By Distribution Channel (USD Million) 2020-2033
- 9.1. Global Dengue Vaccines Market Size, Share and Forecast, By Distribution Channel, 2020-2026
- 9.2. Global Dengue Vaccines Market Size, Share and Forecast, By Distribution Channel, 2027-2033
- 9.3. Synthetic
- 9.4. Bio-Based
10. Global Dengue Vaccines Market Forecast, 2020-2033 (USD Million)
- 10.1. Global Dengue Vaccines Market Size and Market Share
11. Global Dengue Vaccines Market, By Region, 2020-2033 (USD Million)
- 11.1. Global Dengue Vaccines Market Size and Market Share By Region (2020-2026)
- 11.2. Global Dengue Vaccines Market Size and Market Share By Region (2027-2033)
- 11.3. Asia-Pacific
- 11.3.1. Australia
- 11.3.2. China
- 11.3.3. India
- 11.3.4. Japan
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
- 11.4. Europe
- 11.4.1. France
- 11.4.2. Germany
- 11.4.3. Italy
- 11.4.4. Spain
- 11.4.5. United Kingdom
- 11.4.6. Rest of Europe
- 11.5. Middle East and Africa
- 11.5.1. Kingdom of Saudi Arabia
- 11.5.2. United Arab Emirates
- 11.5.3. Qatar
- 11.5.4. South Africa
- 11.5.5. Egypt
- 12.5.6. Morocco
- 11.5.7. Nigeria
- 11.5.8. Rest of Middle-East and Africa
- 11.6. North America
- 11.6.1. Canada
- 11.6.2. Mexico
- 11.6.3. United States
- 11.7. Latin America
- 11.7.1. Argentina
- 11.7.2. Brazil
- 11.7.3. Rest of Latin America
12. Company Profile
- 12.1. Butantan Institute
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. GeneOne Life Science Inc.
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. GlaxoSmithKline Plc
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. Mylan N.V.
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Medigen Vaccine Biologics Corporation
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Merck and Co. Inc.
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Nunn's Home Medical Equipment Company Ltd.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Panacea Biotec Limited
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Sanofi Pasteur Limited
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Serum Institute of India Pvt. Ltd.
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
